Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Neoplasms 5Multiple Myeloma 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Recurrence 1Platinum-resistant Ovarian Cancer 1Metastatic Castration-resistant Prostate Cancer 1Hematologic Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 153Dexamethasone 140Rituximab 83fludarabine 79Cytarabine 69Lenalidomide 68Bortezomib 64fludarabine phosphate 62Gemcitabine 62venetoclax 55Etoposide 53pembrolizumab 52pomalidomide 49Paclitaxel 48Cisplatin 47Carboplatin 47Peripheral Blood Stem Cell Transplantation 46Filgrastim 40Radiotherapy 39Calcium Dobesilate 36Busulfan 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 29Vincristine 28Temozolomide 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Recurrence × afuresertib × Clear all
NCT02235740 2016-05-04

A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)

Novartis

Phase 1 Terminated
1 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡